Feasibility of single-stage direct-to-implant subpectoral breast reconstruction following neoadjuvant chemotherapy for locally advanced breast cancer
Open Access
- 30 January 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (5) , e47123
Abstract
Breast reconstruction is increasingly requested in breast cancer surgery, particularly among young women. However, the criteria for its feasibility need to be more clearly defined. This study aimed to compare the surgical safety and long-term oncologic survival outcomes between immediate breast reconstruction (IBR) and conventional mastectomy (CMx) and to determine the main factors affecting recurrence, considering tumor-specific features. The study analyzed 297 patients with locally advanced breast cancer (stage IIB–IIIC and/or axilla positive) who underwent CMx or IBR between January 2015 and December 2021 at Istanbul University, Oncology Institute, and mainly investigated the outcomes of both surgical interventions regarding recurrence and survival rates. The study examined 132 patients who underwent the CMx and 165 with the IBR procedure. Median follow-up was 60.2 months (range, 12–107). On average, younger patients (43.36 vs 50.42, P < .001) and patients with relatively early-stage tumors ( P = .007, for cT and P = .004, for cN) underwent the IBR procedure more often compared with CMx. There was no difference between the 2 groups regarding other tumor-specific characteristics, receptor profiles, regimens of neoadjuvant chemotherapy, response to neoadjuvant chemotherapy, and adjuvant therapies ( P > .05 for each comparison). The definitive pT stage had the highest risk for local recurrence, with a 3.2-fold increased risk independent of the type of surgery performed ( P < .001, 3.22 (1.56–6.66)). However, no difference was between the IBR and CMx groups regarding local recurrence (84.8% vs 85.6%), distant metastasis (81.2% vs 79.5%), free survival rates, and overall survival (94.95 months vs 93.47 months, P = .916). Immediate breast reconstruction is a safe and feasible approach in patients with locally advanced breast cancer receiving neoadjuvant therapy compared to CMx alone, as it does not affect recurrence rates and survival.Keywords
This publication has 25 references indexed in Scilit:
- ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancerRadiotherapy and Oncology, 2019
- Neoadjuvant Radiotherapy to Facilitate Immediate Breast Reconstruction: A Systematic Review and Current Clinical TrialsAnnals of Surgical Oncology, 2019
- Post-mastectomy immediate breast reconstruction is oncologically safe in well-selected T4 locally advanced breast cancer: a large population-based study and matched case–control analysisBreast Cancer Research and Treatment, 2019
- Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapyMedicine, 2017
- Comparison of immediate breast reconstruction after mastectomy and mastectomy alone for breast cancer: A meta-analysisEuropean Journal of Surgical Oncology, 2017
- The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer stagingCA: A Cancer Journal for Clinicians, 2017
- Oncologic Safety of Immediate Breast Reconstruction for Invasive Breast Cancer Patients: A Matched Case Control StudyJournal of Breast Cancer, 2016
- Locally Advanced Breast Cancer – Strategies for Developing NationsFrontiers in Oncology, 2015
- Breast Reconstruction Outcomes after Nipple-Sparing Mastectomy and Radiation TherapyPlastic and Reconstructive Surgery, 2015
- Immediate Implant-Based Breast Reconstruction following Total Skin-Sparing MastectomyPlastic and Reconstructive Surgery, 2014